Stevenson Ongsyping
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stevenson Ongsyping has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jesus Gomez
Department of Hematology and Oncology, University Medical Center of El Paso, El Paso, TX 79905, USA
3 shared publications - Manas Pustake
Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA
3 shared publications - Mohammad Arfat Ganiyani
Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
3 shared publications - Oboseh John Ogedegbe
Department of Internal Medicine, Trinity Health Ann Arbor Hospital, Ypsilanti, MI 48197, USA
3 shared publications - Atulya Aman Khosla
Department of Internal Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, MI 48073, USA
2 shared publications - Avi Harisingani
Department of Internal Medicine, Loyola MacNeal Hospital, Berwyn, IL 60402, USA
2 shared publications
Latest Publications
- Open Access
Clinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004–2022)
Background: Prostate cancer remains one of the most prevalent malignancies and a leading cause of cancer-related mortality among men in the United States, with more than 300,000 new cases diagnosed annually. As the burden of disease continues to rise, ensuring equitable access to effective treatment remains a critical public health priority. Unequal access to definitive surgical management among disadvantaged populations may contribute to preventable morbidity and mortality. Radical prostatectomy is a cornerstone treatment for localized disease; however, its utilization has evolved over time in response to changing screening guidelines, technological advancements, and shifting treatment paradigms. Despite these developments, disparities in access to surgical management persist. Methods: Using the Surveillance, Epidemiology, and End Results database, we conducted a retrospective cohort study evaluating factors associated with radical prostatectomy utilization among 917,194 men with localized or regional prostate cancer diagnosed between 2004 and 2022. Multivariable logistic regression assessed demographic, socioeconomic, and clinical predictors of surgical treatment. Results: Overall, 33.5% of patients underwent radical prostatectomy. Increasing age was strongly associated with lower odds of surgery (OR 0.904 per year, 95% CI 0.903–0.904, p < 0.001), while married patients were significantly more likely to undergo prostatectomy (OR 1.601, 95% CI 1.554–1.649, p < 0.001). Black patients had markedly lower odds of surgery compared with White patients (OR 0.547, 95% CI 0.539–0.555, p < 0.001), whereas Asian/Pacific Islander patients had slightly higher odds (OR 1.082, p < 0.001). More recent year of diagnosis and increasing income were associated with modest reductions in prostatectomy utilization. Conclusions: These findings demonstrate that treatment selection in prostate cancer is influenced not only by disease characteristics but also by sociodemographic factors, highlighting persistent disparities in access to definitive surgical care and the need for targeted interventions to improve equity in treatment delivery.
Open AccessClinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004–2022)
Background: Prostate cancer remains one of the most prevalent malignancies and a leading cause of cancer-related mortality among men in the United States, with more than 300,000 new cases diagnosed annually. As the burden of disease continues to rise, ensuring equitable access to effective treatment remains a critical public health priority. Unequal access to definitive surgical management among disadvantaged populations may contribute to preventable morbidity and mortality. Radical prostatectomy is a cornerstone treatment for localized disease; however, its utilization has evolved over time in response to changing screening guidelines, technological advancements, and shifting treatment paradigms. Despite these developments, disparities in access to surgical management persist. Methods: Using the Surveillance, Epidemiology, and End Results database, we conducted a retrospective cohort study evaluating factors associated with radical prostatectomy utilization among 917,194 men with localized or regional prostate cancer diagnosed between 2004 and 2022. Multivariable logistic regression assessed demographic, socioeconomic, and clinical predictors of surgical treatment. Results: Overall, 33.5% of patients underwent radical prostatectomy. Increasing age was strongly associated with lower odds of surgery (OR 0.904 per year, 95% CI 0.903–0.904, p < 0.001), while married patients were significantly more likely to undergo prostatectomy (OR 1.601, 95% CI 1.554–1.649, p < 0.001). Black patients had markedly lower odds of surgery compared with White patients (OR 0.547, 95% CI 0.539–0.555, p < 0.001), whereas Asian/Pacific Islander patients had slightly higher odds (OR 1.082, p < 0.001). More recent year of diagnosis and increasing income were associated with modest reductions in prostatectomy utilization. Conclusions: These findings demonstrate that treatment selection in prostate cancer is influenced not only by disease characteristics but also by sociodemographic factors, highlighting persistent disparities in access to definitive surgical care and the need for targeted interventions to improve equity in treatment delivery.
- Open Access
Sociodemographic Factors and Treatment Patterns Associated with Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000–2022)
Background: Splenic marginal zone lymphoma (SMZL) is a rare indolent lymphoma with extremely limited population-level evidence on social and treatment correlates of survival. Methods: We conducted a retrospective cohort study using SEER (2000 to 2022) to evaluate OS in primary SMZL (ICD O 3 9689; spleen C42.2). We summarized baseline features and treatments and used Kaplan–Meier and Cox regression. Results: The cohort included 3548 patients (mean age: 68.2 years; 53.6% female). Most were White (89.8%) and non-Hispanic (92.1%). The Ann Arbor stage was missing in 39.4%. Treatment included systemic antineoplastic therapy in 26.4%, beam radiation in 0.7%, and primary site surgery in 21.4%. At last follow-up, 56.8% were alive; non-Hodgkin lymphoma accounted for 15.8% deaths in the cohort, with substantial competing causes including heart disease (6.1%). In multivariable Cox analysis, OS was independently associated with age (HR 1.082 per year, 95% CI 1.072–1.091), male sex (HR 1.34, 95% CI 1.14–1.57), Hispanic ethnicity (HR 1.42, 95% CI 1.08–1.88), systemic antineoplastic therapy (HR 1.42, 95% CI 1.18–1.70), divorced/separated marital status vs. married (HR 1.35, 95% CI 1.03–1.77), and stage IV disease (HR 1.70, 95% CI 1.16–2.50). Race and year of diagnosis were not independently associated with OS in the adjusted model. Conclusions: In our large population-based analysis, OS in SMZL tracks with demographic and social variables and competing risks. Stage missingness and treatment selection limit causal inference for management effects.
Open AccessSociodemographic Factors and Treatment Patterns Associated with Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000–2022)
Background: Splenic marginal zone lymphoma (SMZL) is a rare indolent lymphoma with extremely limited population-level evidence on social and treatment correlates of survival. Methods: We conducted a retrospective cohort study using SEER (2000 to 2022) to evaluate OS in primary SMZL (ICD O 3 9689; spleen C42.2). We summarized baseline features and treatments and used Kaplan–Meier and Cox regression. Results: The cohort included 3548 patients (mean age: 68.2 years; 53.6% female). Most were White (89.8%) and non-Hispanic (92.1%). The Ann Arbor stage was missing in 39.4%. Treatment included systemic antineoplastic therapy in 26.4%, beam radiation in 0.7%, and primary site surgery in 21.4%. At last follow-up, 56.8% were alive; non-Hodgkin lymphoma accounted for 15.8% deaths in the cohort, with substantial competing causes including heart disease (6.1%). In multivariable Cox analysis, OS was independently associated with age (HR 1.082 per year, 95% CI 1.072–1.091), male sex (HR 1.34, 95% CI 1.14–1.57), Hispanic ethnicity (HR 1.42, 95% CI 1.08–1.88), systemic antineoplastic therapy (HR 1.42, 95% CI 1.18–1.70), divorced/separated marital status vs. married (HR 1.35, 95% CI 1.03–1.77), and stage IV disease (HR 1.70, 95% CI 1.16–2.50). Race and year of diagnosis were not independently associated with OS in the adjusted model. Conclusions: In our large population-based analysis, OS in SMZL tracks with demographic and social variables and competing risks. Stage missingness and treatment selection limit causal inference for management effects.
- Open Access
- 26 February 2026
- Published by MDPI AG in Preprints.org
Sociodemographic Factors and Treatment Patterns Associated with Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000-2022)
Background: Splenic marginal zone lymphoma (SMZL) is a rare indolent lymphoma with extremely limited population level evidence on social and treatment correlates of survival. Methods: We conducted a retrospective cohort study using SEER (2000 to 2022) to evaluate OS in primary SMZL (ICD O 3 9689; spleen C42.2). We summarized baseline features and treatments and used Kaplan Meier and Cox regression. Results: The cohort included 3,548 patients (mean age 68.2 years; 53.6% female). Most were White (89.8%) and non Hispanic (92.1%). Ann Arbor stage was missing or blank in 39.4%. Initial therapy included chemotherapy in 26.4%, beam radiation in 0.7%, and primary site surgery in 21.4%. At last follow up, 56.8% were alive; non Hodgkin lymphoma accounted for 15.8% of the full cohort, with substantial competing causes including heart disease (6.1%). In multivariable Cox analysis, OS was independently associated with age (HR 1.073 per year, 95% CI 1.067 to 1.079), male sex (HR 1.337, 95% CI 1.203 to 1.486), Hispanic ethnicity (HR 1.426, 95% CI 1.194 to 1.703), chemotherapy (HR 1.246, 95% CI 1.118 to 1.390), year of diagnosis (HR 0.983 per category, 95% CI 0.973 to 0.993), marital status (married vs divorced HR 0.720, 95% CI 0.600 to 0.863), and race (Asian or Pacific Islander vs White HR 3.210, 95% CI 1.164 to 8.853). Conclusions: In our large population based analysis, OS in SMZL tracks with demographic and social variables and competing risks. Stage missingness and treatment selection limit causal inference for management effects.
- 26 February 2026
- Published by MDPI AG in Preprints.org
Open AccessSociodemographic Factors and Treatment Patterns Associated with Overall Survival in Splenic Marginal Zone Lymphoma: A Nationwide Retrospective Cohort Study (2000-2022)
Background: Splenic marginal zone lymphoma (SMZL) is a rare indolent lymphoma with extremely limited population level evidence on social and treatment correlates of survival. Methods: We conducted a retrospective cohort study using SEER (2000 to 2022) to evaluate OS in primary SMZL (ICD O 3 9689; spleen C42.2). We summarized baseline features and treatments and used Kaplan Meier and Cox regression. Results: The cohort included 3,548 patients (mean age 68.2 years; 53.6% female). Most were White (89.8%) and non Hispanic (92.1%). Ann Arbor stage was missing or blank in 39.4%. Initial therapy included chemotherapy in 26.4%, beam radiation in 0.7%, and primary site surgery in 21.4%. At last follow up, 56.8% were alive; non Hodgkin lymphoma accounted for 15.8% of the full cohort, with substantial competing causes including heart disease (6.1%). In multivariable Cox analysis, OS was independently associated with age (HR 1.073 per year, 95% CI 1.067 to 1.079), male sex (HR 1.337, 95% CI 1.203 to 1.486), Hispanic ethnicity (HR 1.426, 95% CI 1.194 to 1.703), chemotherapy (HR 1.246, 95% CI 1.118 to 1.390), year of diagnosis (HR 0.983 per category, 95% CI 0.973 to 0.993), marital status (married vs divorced HR 0.720, 95% CI 0.600 to 0.863), and race (Asian or Pacific Islander vs White HR 3.210, 95% CI 1.164 to 8.853). Conclusions: In our large population based analysis, OS in SMZL tracks with demographic and social variables and competing risks. Stage missingness and treatment selection limit causal inference for management effects.